SCHEMBL23914876

SCHEMBL23914876

FC(F)(F)COc1cc2cn[nH]c2cc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 12/20 0.49
TRPM8 Q7Z2W7 5/20 0.49
TRPV1 Q8NER1 4/20 0.49
METAP2 P50579 1/20 0.43
CNR2 P34972 2/20 0.41
NOS1 P29475 2/20 0.39
DYRK1A Q13627 1/20 0.39
AXL P30530 1/20 0.38
CHEK1 O14757 1/20 0.38
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
USP2 O75604 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HSP90AA1 P07900 1/20 0.37
HSP90AB1 P08238 1/20 0.37
MAPT P10636 1/20 0.37
THRB P10828 1/20 0.37
G6PD P11413 1/20 0.37
ALOX15 P16050 1/20 0.37
CASP1 P29466 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23915494 0.80 TRPA1 (0.49) TRPA1TRPM8TRPV1NOS1DYRK1A
SCHEMBL23914877 0.79 TRPA1 (0.40) TRPA1TRPM8TRPV1NOS1DYRK1A
SCHEMBL23909011 0.75 TRPA1 (0.53) TRPA1TRPM8TRPV1CNR2NOS1
SCHEMBL29109556 0.74 AXL (0.60) TRPA1TRPM8TRPV1NOS1DYRK1A
SCHEMBL23915491 0.74 TRPA1 (0.52) TRPA1NOS1DYRK1AAXLCHEK1
SCHEMBL25346085 0.74 METAP2 (0.46) TRPA1TRPM8TRPV1METAP2NOS1
SCHEMBL25344307 0.73 METAP2 (0.57) TRPA1METAP2NOS1DYRK1AAXL
SCHEMBL28814958 0.73 MEN1 (0.48) TRPA1TRPM8METAP2NOS1KDM4E
SCHEMBL3590783 0.71 NOS1 (0.57) TRPA1TRPM8TRPV1METAP2NOS1
SCHEMBL24358709 0.71 AXL (0.48) TRPA1TRPM8NOS1DYRK1AAXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3649119-B1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS GALAPAGOS NV (BE) 2021-11-03 EP disclosed
US-20210315893-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS GILEAD SCIENCES, INC. 2021-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210315893-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS S1PR1, S1PR3, S1PR2 TRPA1 656/4885TRPM8 1596/4885TRPV1 316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.